3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
132
Recurrence
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasms, Plasma Cell
15
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia
7
Immunoglobulin Light-chain Amyloidosis
7
Lymphoma, Non-Hodgkin
6
Amyloidosis
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Burkitt Lymphoma
5
Paraproteinemias
4
Lymphoma, Mantle-Cell
4
Leukemia, Myeloid, Acute
4
Hematologic Diseases
4
Blood Protein Disorders
4
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Corneal Diseases
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Interventions
Paclitaxel
10
Radiotherapy
7
Fluorouracil
7
pembrolizumab
6
Carboplatin
6
Oxaliplatin
5
Cisplatin
5
lenvatinib
3
Neoadjuvant Therapy
3
Cetuximab
3
tislelizumab
2
camrelizumab
2
Surgical Procedures, Operative
2
Nivolumab
2
Leucovorin
2
Irinotecan
2
Drug Therapy
2
Docetaxel
2
tremelimumab
1
toripalimab
1
regorafenib
1
osimertinib
1
oblimersen
1
nimotuzumab
1
nedaplatin
1
monalizumab
1
enzalutamide
1
durvalumab
1
aflibercept
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Esophageal Squamous Cell Carcinoma
×
Dexamethasone
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled